Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure
| Errataetall: |
CommentOn: Circulation. 2024 Mar 12;149(11):825-838. - PMID 38059368 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
Circulation - 149(2024), 11 vom: 12. März, Seite 839-842 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cleland, John G F [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.03.2024 Date Revised 03.04.2024 published: Print-Electronic CommentOn: Circulation. 2024 Mar 12;149(11):825-838. - PMID 38059368 Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCULATIONAHA.123.068089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369565177 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369565177 | ||
| 003 | DE-627 | ||
| 005 | 20240404235004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240312s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCULATIONAHA.123.068089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM369565177 | ||
| 035 | |a (NLM)38466791 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cleland, John G F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nature and Magnitude of the Benefits of Dapagliflozin and Empagliflozin for Heart Failure |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2024 | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Circulation. 2024 Mar 12;149(11):825-838. - PMID 38059368 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Editorials | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a sodium-glucose transporter 2 inhibitors | |
| 650 | 4 | |a symptoms | |
| 650 | 4 | |a trials | |
| 650 | 7 | |a empagliflozin |2 NLM | |
| 650 | 7 | |a HDC1R2M35U |2 NLM | |
| 650 | 7 | |a dapagliflozin |2 NLM | |
| 650 | 7 | |a 1ULL0QJ8UC |2 NLM | |
| 650 | 7 | |a Benzhydryl Compounds |2 NLM | |
| 650 | 7 | |a Glucosides |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d 1950 |g 149(2024), 11 vom: 12. März, Seite 839-842 |w (DE-627)NLM000039020 |x 1524-4539 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2024 |g number:11 |g day:12 |g month:03 |g pages:839-842 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCULATIONAHA.123.068089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2024 |e 11 |b 12 |c 03 |h 839-842 | ||